‌

US Patent 12090234 Compositions and methods related to megakaryocyte-derived extracellular vesicles

Patent 12090234 was granted and assigned to STRM.Bio Incorporated on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

STRM.Bio Incorporated

0

Current Assignee

STRM.Bio Incorporated

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jonathan Thon0

Date of Patent

September 17, 2024

0

Patent Application Number

181008210

Date Filed

January 24, 2023

0

Patent Citations

US Patent 10370663 Delivery of therapeutic agent

0

US Patent 10538738 Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells

0

US Patent 10561740 Preparation of therapeutic exosomes using membrane proteins

0

US Patent 10695443 Exosome transfer of nucleic acids to cells

0

US Patent 10723782 Exosomes for immuno-oncology and anti-inflammatory therapy

0

US Patent 11512315 Methods and compositions for macrophage polarization

0

US Patent 9085778 Exosome transfer of nucleic acids to cells

0

US Patent 9629929 Exosome transfer of nucleic acids to cells

0

...

Patent Primary Examiner

Bethany P Barham

0

Patent abstract

Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12090234 Compositions and methods related to megakaryocyte-derived extracellular vesicles

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.